Malaria,Falciparum Clinical Trial
Official title:
A Household Randomized Control Trial of Insecticide-treated Eave Nets and Window Screens for Malaria Control in Chalinze District, Tanzania.
This is a household randomized trial of a new tool for house modification, Insecticide-Treated Eave nets (ITENs) in combination with insecticide-treated window screens (ITWS), coated with a dual active ingredient (dual AI): Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m² and PBO synergist at 10g/kg which corresponds to 480 mg/m², as used in the so-called dual-AI LLIN or "resistance breaking" nets for resistance malaria vector control. Four hundred and fifty (450) households with intact walls, opened eaves, and those without screens or nets on the windows in Chalinze district, Tanzania will be eligible and only recruited upon written informed consent. The households will be randomly allocated into two arms: one with ITENs and ITWS installed and the other without. The primary outcome will be malaria parasite detection in household residents aged over 6 months old using a quantitative Polymerase Chain Reaction (qPCR) at approximately 12 months post-installation, coinciding with the long rainy season.
In Tanzania, long-lasting insecticidal nets (LLINs) contributed to the high reduction of malaria in the last decade. However, malaria reduction in Tanzania is threatened due to increasing insecticidal resistance of malaria vectors, low access to LLIN, LLINs not lasting up to three years, and net usage compliance. Therefore, it is evident that an additional cost-effective vector control tool is required that may confer protection against resistant malaria vectors, protect every member of the household, requires little or less compliance to use after distribution, and lasts longer. The proposed additional vector control tool for trial is the Insecticide-Treated Eave nets (ITENs) in combination with Insecticide Treated Window screens (ITWS) for house modification. The tool is coated with a dual active ingredient (dual AI): Deltamethrin at 3g AI/kg, which corresponds to 144 mg/m², and PBO synergist at 10g/kg which corresponds to 480 mg/m², which are coated at the same concentration in insecticide-treated nets that are already in use in the population to control pyrethroid-resistant mosquitoes. These can protect everyone in the house by blocking mosquito entry and killing mosquitos that contact them to protect everyone in the community. In this trial, 450 households will be randomly allocated into two arms. One arm with ITENs & ITWS installed and the other without to serve as the control arm. The 450 households are recruited and assigned codes during baseline data collection. The assigned codes are randomized to either of the two arms by simple randomization in STATA and stratified by sub-village. Approximately 6 months and 12 months post-installation, coinciding with the rainy seasons, clinical officers will screen for malaria parasites in household residents of over 6 months old (it is estimated that 4.4 persons reside in each household, thus approx. 1,800 persons will be screened for malaria per survey) in both arms and confirmation of malaria parasite will be done using qPCR analysis as the primary assessment of the primary outcome. As a point of care, SD Bioline Malaria Ag Pf/Pan rapid diagnostic test (RDT) as per Tanzanian guidelines will also be conducted on all household residents. Any participant (s) with an axillary temperature of 37.5 degrees (fever) and that test positive using mRDT will be considered as a clinical malaria case. All malaria-positive participants will be treated using free Artemether Lumefantrine (ALu). This drug is approved by the national guideline for the treatment of uncomplicated malaria. Other secondary objectives are: - To evaluate malaria prevalence in households with ITENs & ITWS and those without at approximately 6 months post-installation, coinciding with the short rainy season. - To determine the prevalence of clinical malaria defined by an axillary temperature of 37.5 degrees and above (fever) and mRDT malaria positive cases at approximately 6 months and 12 months post-installation, coinciding with the rainy seasons. - To investigate the effect of ITENs and ITWS on the density of malaria vectors and nuisance (Culex quinquefasciatus) mosquitoes in the community at approximately 6 months and 12 months post-installation, coinciding with the rainy seasons using Centres for Disease Control (CDC) light traps. - To assess the number of fabric in meters and time of installing the intervention (feasibility of scaling-up ITENs and ITWS use) in local houses in the field during installation. - To assess the adverse effects of ITENs and ITWS in the community. - To determine the attrition and fabric integrity of ITENs and ITWS in the field post 6 months and 12 months of installation. - To determine the mortality induced by (bioefficacy) ITENs and ITWS on laboratory-reared mosquitoes post 12 months of installation. - To determine the insecticide retainment of ITENs and ITWS post 12 months of installation. - To assess the acceptability of ITENs and ITWS to the local community post 6 months and 12 months of installation. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04130282 -
VAC077: Safety and Immunogenicity of the Pfs25-IMX313/Matrix-M Vaccine
|
Phase 1 | |
Completed |
NCT04049916 -
Pyronaridine-artesunate With Low Dose Primaquine for Preventing P. Falciparum Transmission
|
Phase 2/Phase 3 | |
Active, not recruiting |
NCT03814616 -
Pyramax in Asymptomatic Carriers of P. Falciparum Monoinfections
|
Phase 2 | |
Active, not recruiting |
NCT04079621 -
Short Course Radical Cure of P. Vivax Malaria in Nepal
|
Phase 4 | |
Completed |
NCT05135273 -
Study of the Transmission-Blocking Vaccine Pfs230D1-EPA/Matrix-M Against Malaria in Adults in Mali
|
Phase 1 | |
Not yet recruiting |
NCT06083688 -
Preventing Malaria in School Children to Protect the Whole Community in Rural Blantyre District, Malawi
|
Phase 4 | |
Recruiting |
NCT03511443 -
Evaluation of the Performance of a hsRDT Versus cRDT in Reactive Case Detection of Malaria Infections
|
N/A | |
Completed |
NCT05550909 -
Gametocytocidal and Transmission-blocking Efficacy of ASAQ and ALAQ With or Without PQ in Mali
|
Phase 2 | |
Recruiting |
NCT05306067 -
Plasmodium Falciparum Genomic Intelligence in Mozambique
|
||
Completed |
NCT05081089 -
Gametocytocidal and Transmission-blocking Efficacy of PQ in Combination With AL and TQ in Combination With SPAQ in Mali
|
Phase 2 | |
Recruiting |
NCT05150808 -
Vectron T500 (Broflanilide 50WP) for IRS in Tanzania Tanzania
|
Phase 3 | |
Recruiting |
NCT05757167 -
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics
|
Phase 4 | |
Completed |
NCT01992900 -
A Pharmacokinetic/Pharmacodynamic Study of Eurartesim Dispersible Formulation in Infants With P.Falciparum Malaria
|
Phase 2 | |
Completed |
NCT04565184 -
Effectiveness and Safety of Artesunate-Amodiaquine and Artemether-Lumefantrine for the Treatment of Malaria in Yaounde
|
Phase 4 | |
Completed |
NCT03896724 -
Safety, Immunogenicity and Efficacy of R21 Matrix-M in 5-17 Month Old Children in Nanoro, Burkina Faso
|
Phase 1/Phase 2 | |
Completed |
NCT03454048 -
Controlled Human Malaria Infection Model for Evaluation of Transmission-blocking Interventions - Study 2
|
N/A | |
Recruiting |
NCT04844905 -
Adjunctive Ivermectin Mass Drug Administration for Malaria Control
|
Phase 3 | |
Completed |
NCT03138096 -
Safety and Protective Efficacy of Pb(PfCS@UIS4)
|
Phase 1/Phase 2 | |
Recruiting |
NCT04271306 -
Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.
|
Phase 1 | |
Recruiting |
NCT05058885 -
Plasmodium Vivax Among Duffy Negative Population in Cameroon.
|